Mr. Pedro Antonio Regidor | Medizin Und Gutartige Erkrankungen | Best Researcher Award
PD Dr. med | Exeltis Healthcare | Germany
Dr. Paul A. Regidor is a distinguished German-Spanish gynecologist with over three decades of experience in women’s health, specializing in gynecology, obstetrics, reproductive medicine, endocrinology, and oncology. A dual citizen of Germany and Spain, Dr. Regidor has led the Department of Gynecology and Obstetrics at Frauenklinik München West, one of Germany’s premier institutions. His clinical expertise is complemented by a robust academic career marked by a strong commitment to patient care, surgical innovation, and translational research. He earned his medical doctorate from the University of Essen in 1992 with a dissertation on immunohistochemical determination of progesterone receptors. In 2000, he was awarded the in gynecology and obstetrics at the same university. Dr. Regidor holds key roles in multiple national and international scientific societies and has served as an advisor to pharmaceutical companies such as Lipocine Inc. His research has focused on endometriosis, hormone therapy, and gynecological oncology, with numerous publications in peer-reviewed journals. He is a founding member of the Breast Center in Münster and a valued member of various scientific advisory boards. Dr. Regidor’s career exemplifies clinical excellence, academic leadership, and a lifelong dedication to advancing women’s health.
Professional Profile
Education
His dissertation, titled reflects his early interest in hormonal regulation and tissue response—an area that would define his future specialization. He achieved full medical allowing him to practice medicine in Germany. In 1995, he was certified as a Specialist in Gynecology and Obstetrics. Subsequently, he attained further specializations in Gynecological Endocrinology and Reproductive Medicine, and in Gynecological Oncology—credentials that enabled him to handle a wide spectrum of female reproductive health challenges.ollowing a resolution by the faculty council, he was granted for gynecology and obstetrics and was appointed at the University of Essen. His educational credentials are distinguished by both clinical depth and academic rigor, aligning theoretical insight with hands-on practice. His multidisciplinary medical education has been fundamental in shaping his work in reproductive endocrinology, hormonal therapeutics, and gynecologic cancers.
Experience
Dr. Paul A. Regidor brings extensive clinical, academic, and advisory experience. Since his initial certification as a specialist in 1995, he has steadily built a career at the intersection of clinical excellence and scientific inquiry. He is currently the Head of the Department of Gynecology and Obstetrics at Frauenklinik München West in Munich, Germany, where he oversees medical and surgical care, particularly in high-risk pregnancies, oncology, and hormonal therapies. He has been a at the University of Essen since 2000, contributing to the training of medical students and gynecological residents. His professional background also includes service as a founding member and coordinator of the Breast Center Münster, a facility focused on multidisciplinary breast cancer care. Beyond Germany, Dr. Regidor serves as a consultant for Lipocine Inc., USA, providing expertise on female hormone replacement therapies. He is actively involved in several scientific societies and clinical working groups, where he collaborates on clinical guidelines, restorative gynecological surgeries, and endocrine therapies. His contributions to international boards and advisory panels reflect his global standing as a subject-matter expert. Throughout his career, Dr. Regidor has maintained a balanced commitment to patient care, translational research, and academic mentorship.
Research Focus
Dr. Regidor’s research primarily addresses female reproductive health with emphases on gynecological endocrinology, reproductive medicine, and gynecologic oncology. His work explores the molecular and histological basis of hormonal disorders, particularly progesterone and estrogen pathways, contributing to better diagnostic and therapeutic protocols. He has made significant strides in understanding and managing endometriosis, from gene deregulation (e.g., Cyr61) to in vivo modeling and morphometric tissue analyses. His early research on the immunohistochemical identification of progesterone receptors laid the foundation for his later investigations into hormone-responsive conditions. Additionally, his clinical trials on antibiotic prophylaxis in cesarean sections underscore his contributions to infection control in obstetric practice. He is actively involved in advancing hormone replacement therapy for menopausal women and has advised pharmaceutical innovations in this field. His interdisciplinary collaborations with pathologists, molecular biologists, and surgeons have yielded impactful publications and real-world clinical applications. Dr. Regidor is also engaged in studies on tumor biology, particularly in gynecologic oncology, where he explores molecular markers for early detection and treatment. With roles on multiple scientific advisory boards and clinical working groups, he continues to shape the evolving landscape of women’s health through research that bridges clinical care and molecular insight.
Awards and Honors
Dr. Regidor’s career is marked by prestigious academic and professional honors. In 1992, he earned the Doctor of Medicine (Dr. med.) degree for his seminal dissertation on progesterone receptor detection, a work that bridged immunohistochemistry and gynecological endocrinology. His academic stature was further recognized when the University of Essen conferred upon him the for gynecology and obstetrics and appointed him in 2000. He has been entrusted with advisory roles in globally recognized institutions and pharmaceutical companies, notably as a consultant to Lipocine Inc. in the United States for their hormone replacement therapy program. Dr. Regidor is a founding member and coordinator of the Breast Center Münster, an honor demonstrating leadership in women’s oncology. His active participation in multiple scientific societies—such as the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Niederrheinisch-Westfälische Gesellschaft, and Westdeutsches Tumorzentrum—has earned him recognition as a thought leader. He has also been appointed to several scientific advisory boards, including the Stiftung Endometriose Forschung and E.E.I.C. Vereins, reflecting his influence in guiding reproductive and oncological research. These honors underscore a career dedicated to clinical innovation, academic contribution, and improving women’s reproductive health on a national and international level.
Publication Top Notes
1. “The drospirenone only pill as a contraceptive option for breastfeeding women: First data on users’ acceptability and newborn development”
2. “OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF A NEW VAGINAL PESSARY CONTAINING 300MG TINIDAZOLE, 200MG TIOCONAZOLE AND 100MG LIDOCAINE”
3. “Nausea and Vomiting of Pregnancy and its Management with the Dual-Release Formulation of Doxylamine and Pyridoxine”
4. “Antibiotic prophylaxis in cesarean section — piperacillin versus piperacillin/tazobactam in 300 cesarean sections”
5. “Cyr61, a deregulated gene in endometriosis”